April 2020 HSC Section 4 - Plastic and Reconstructive Problems

J A M A CAD D ERMATOL J ULY 2017

Adil and Godwin

11. Kim H, Choi JW, Kim JY, Shin JW, Lee SJ, Huh CH. Low-level light therapy for androgenetic alopecia: a 24-week, random- ized, double-blind, sham device-controlled multicenter trial. Dermatol Surg . 2013;39(8):1177-1183 . 12. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol . 2007;57(5):767-774 . 13. Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol . 2003;149(2):354-362 . 14. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol . 2002;47(3):377-385 . 15. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol . 2004;50(4):541-553 . 16. DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol . 1994;130(3):303-307 . 17. Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol . 1993;32(10):758-762 . 18. Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol . 1992;31(11): 800-804 . 19. Olsen EA. Topical minoxidil in the treatment of androgenetic alopecia in women (28 women). Cutis . 1991;48(3):243-248 . 20. Shupack JL, Kassimir JJ, Thirumoorthy T, Reed ML, Jondreau L. Dose-response study of topical minoxidil in male pattern alope- cia. J Am Acad Dermatol . 1987;16(3 Pt 2):673-676 . 21. Roberts JL. Androgenetic alopecia: treatment results with topical minoxidil. J Am Acad Dermatol . 1987;16(3 Pt 2):705-710 . 22. Petzoldt D. The German double-blind placebo-controlled evaluation of topical minoxidil solution in the treatment of early male pattern baldness. Int J Dermatol . 1988;27(6 suppl): 430-434 . 23. Olsen EA, Weiner MS, Delong ER, Pinnell SR. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol . 1985;13(2 Pt 1):185-192 . 24. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol . 2002;12(1):32-37 . 25. Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol . 2000;143(4):804-810 . 26. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol . 1999;40(6 Pt 1):930-937 . 27. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc . 1999;4(3):282-284 . 28. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol . 2010;63(2):252-258 . 29. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5a-reductase inhibition in the treatment of male pattern

Fig 3. Funnel plot for all the included studies in this meta- analysis assessing treatments for androgenetic alopecia.

measures, such as patient satisfaction or investigator rating using photos at various time points. While these could be considered softer outcomes they might, in fact, be a truer reflection of the clinical significance of these results. Hair loss is a disorder that often affects the self-esteem of an individual; visibly significant results are required to help patients in that regard. REFERENCES 1. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science . 1974;186: 1213-1215 . 2. Kaufman KD, Girman CJ, Round EM, Johnson-Levonas AO, Shah AK, Rotonda J. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol . 2008;18(4):407-411 . 3. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci . 1951;53(3):708-728 . 4. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc . 2005; 10(3):184-189 . 5. Krupa Shankar DS, Chakravarthi M, Shilpakar R. Male andro- genetic alopecia: population-based study in 1,005 subjects. Int J Trichology . 2009;1(2):131-133 . 6. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol . 1992;26(6):926-931 . 7. Cash TF, Price VH, Savin RC. Psychological effects of androge- netic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol . 1993;29(4): 568-575 . 8. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol . 1977;97(3):247-254 . 9. Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig . 2009;29(5):283-292 . 10. Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernandez-Obregon A, Kazmirek ER. The Growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med . 2013;45:487-495 .

92